Geller R B, Vogelsang G B, Wingard J R, Yeager A M, Burns W H, Santos G W, Saral R
Johns Hopkins Hospital, Oncology Center, Baltimore, MD 21205.
J Clin Oncol. 1988 Oct;6(10):1558-61. doi: 10.1200/JCO.1988.6.10.1558.
Five patients with acute myelocytic leukemia (AML) after combined modality therapy for Hodgkin's disease (HD) were treated with cyclophosphamide and busulfan followed by bone marrow transplantation (BMT). Four patients received allogeneic transplants from histocompatibility locus antigen (HLA)-compatible siblings and the fifth patient received an autologous marrow treated with 4-hydroperoxycyclophosphamide. Two patients died of complications of acute graft-v-host disease (GVHD) despite prophylaxis with either low-dose cyclophosphamide or cyclosporine. The remaining three patients were alive and disease-free 382, 617, and 620 days after transplant. These initial results are encouraging and more patients with treatment-related AML need to be evaluated with both allogeneic and autologous BMT to fully elucidate the potentially curative role of this intensive therapy in an otherwise fatal hematologic malignancy.
5例霍奇金病（HD）综合治疗后发生急性髓细胞白血病（AML）的患者接受了环磷酰胺和白消安治疗，随后进行了骨髓移植（BMT）。4例患者接受了来自组织相容性位点抗原（HLA）匹配同胞的异基因移植，第5例患者接受了用4-氢过氧环磷酰胺处理的自体骨髓。尽管采用低剂量环磷酰胺或环孢素进行预防，仍有2例患者死于急性移植物抗宿主病（GVHD）并发症。其余3例患者在移植后382、617和620天存活且无疾病。这些初步结果令人鼓舞，需要对更多治疗相关AML患者进行异基因和自体BMT评估，以充分阐明这种强化治疗在这种致命血液系统恶性肿瘤中潜在的治愈作用。
